Signet Financial Management LLC Purchases 368 Shares of Amgen Inc. (NASDAQ:AMGN)

Signet Financial Management LLC boosted its position in Amgen Inc. (NASDAQ:AMGN) by 5.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,112 shares of the medical research company’s stock after acquiring an additional 368 shares during the period. Signet Financial Management LLC’s holdings in Amgen were worth $1,769,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. Security National Trust Co. raised its stake in Amgen by 0.4% during the 4th quarter. Security National Trust Co. now owns 10,089 shares of the medical research company’s stock valued at $2,320,000 after buying an additional 40 shares during the last quarter. Moody Lynn & Lieberson LLC grew its position in shares of Amgen by 2.6% during the 1st quarter. Moody Lynn & Lieberson LLC now owns 1,565 shares of the medical research company’s stock valued at $389,000 after acquiring an additional 40 shares during the period. Lederer & Associates Investment Counsel CA grew its position in shares of Amgen by 0.4% during the 1st quarter. Lederer & Associates Investment Counsel CA now owns 10,280 shares of the medical research company’s stock valued at $2,558,000 after acquiring an additional 41 shares during the period. Aspiriant LLC grew its position in shares of Amgen by 2.1% during the 4th quarter. Aspiriant LLC now owns 2,055 shares of the medical research company’s stock valued at $473,000 after acquiring an additional 42 shares during the period. Finally, Nachman Norwood & Parrott Inc grew its position in shares of Amgen by 0.5% during the 4th quarter. Nachman Norwood & Parrott Inc now owns 8,816 shares of the medical research company’s stock valued at $2,027,000 after acquiring an additional 43 shares during the period. Institutional investors and hedge funds own 75.23% of the company’s stock.

AMGN opened at $251.38 on Monday. The firm has a 50-day simple moving average of $250.67 and a two-hundred day simple moving average of $237.27. Amgen Inc. has a 52 week low of $210.28 and a 52 week high of $276.69. The company has a market capitalization of $144.43 billion, a PE ratio of 20.27, a price-to-earnings-growth ratio of 1.90 and a beta of 0.76. The company has a quick ratio of 1.88, a current ratio of 2.28 and a debt-to-equity ratio of 3.12.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Monday, April 26th. The medical research company reported $3.70 EPS for the quarter, missing the consensus estimate of $4.05 by ($0.35). The company had revenue of $5.90 billion for the quarter, compared to the consensus estimate of $6.30 billion. Amgen had a net margin of 29.42% and a return on equity of 95.55%. The firm’s revenue for the quarter was down 4.2% on a year-over-year basis. During the same period last year, the company earned $4.17 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 16.15 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 8th. Stockholders of record on Monday, May 17th will be given a dividend of $1.76 per share. This represents a $7.04 annualized dividend and a dividend yield of 2.80%. The ex-dividend date is Friday, May 14th. Amgen’s dividend payout ratio is 47.50%.

A number of equities research analysts have recently issued reports on AMGN shares. Evercore ISI reissued a “buy” rating on shares of Amgen in a research report on Thursday, April 29th. Cantor Fitzgerald boosted their price objective on shares of Amgen from $280.00 to $295.00 and gave the company an “overweight” rating in a research report on Wednesday, February 3rd. Barclays cut their price objective on shares of Amgen from $242.00 to $230.00 and set an “equal weight” rating for the company in a research report on Thursday, March 11th. Morgan Stanley dropped their target price on shares of Amgen from $281.00 to $278.00 and set an “overweight” rating for the company in a report on Monday, May 3rd. Finally, SVB Leerink dropped their target price on shares of Amgen from $267.00 to $230.00 and set a “market perform” rating for the company in a report on Tuesday, May 4th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $255.86.

In other news, Director Ronald D. Sugar sold 1,000 shares of the company’s stock in a transaction dated Wednesday, March 10th. The shares were sold at an average price of $231.53, for a total transaction of $231,530.00. Following the sale, the director now directly owns 16,805 shares in the company, valued at approximately $3,890,861.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 2,500 shares of the company’s stock in a transaction dated Tuesday, May 11th. The shares were sold at an average price of $252.51, for a total transaction of $631,275.00. Following the sale, the senior vice president now owns 14,961 shares in the company, valued at $3,777,802.11. The disclosure for this sale can be found here. Insiders have sold a total of 5,750 shares of company stock worth $1,426,320 over the last 90 days. Corporate insiders own 0.36% of the company’s stock.

Amgen Company Profile

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA.

Further Reading: Day Trading – Risk Worth the Reward?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.